CELCUITY
PharmaCELCUITY is a pharmaceutical company focused on Oncology. Key products include REVTORPYK.
CELCUITY's Key Drugs
CELCUITY's core commercial portfolio centers on REVTORPYK, spanning Oncology — its most strategically important drugs approved in the last 15 years.
CELCUITY News
All CELCUITY news →- Nov 9, 2026 RegulatoryCelcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer ↗
- Nov 5, 2026 EarningsCelcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update ↗
- Oct 24, 2026 TrialsCelcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026 ↗
- Oct 23, 2026 TrialsCelcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026 ↗
- Oct 5, 2026 TrialsCelcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026 ↗
CELCUITY's Recent FDA Approvals
CELCUITY secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
CELCUITY's Therapeutic Areas
CELCUITY's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CELCUITY's Top Competitors
CELCUITY's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CELCUITY Pipeline Snapshot
CELCUITY has 4 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 0 Phase 2 and 2 Phase 1.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • REVTORPYK leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2026-07-14
- Latest
- 2026-07-14
- Applications
- 1